EUVIMEDObjevte EUVIMED
KohortenstudieOpen access · CC BY-NC 4.0

A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk

Karl Mårild, Jonas Söderling, Jordan Axelrad iD, Jonas Halfvarson, Anders Forss iD, SWIBREG Study Group, Karl Michaëlsson, Ola Olén, Jonas F Ludvigsson iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18275 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2024. Written by Karl Mårild and 8 co-authors. Institution: Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden. Major MEDLINE topics: Inflammatory Bowel Diseases, Fractures, Bone. Cited 10 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIDDK NIH HHS, Vetenskapsrådet, Svenska Sällskapet för Medicinsk Forskning.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity.

Aims

To determine the fracture risk in IBD during periods with and without histological inflammation.

Methods

We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990–2016 with longitudinal data on ileo‐colorectal biopsies. Fractures were identified by inpatient and hospital‐based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio‐demographics, comorbidities, IBD duration, IBD‐related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.

Results

Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29–1.46) fractures per 100 years' follow‐up versus 1.31 (95% CI 1.19–1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00–1.26; p = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91–1.36) and ulcerative colitis (1.18; 95% CI 1.02–1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid‐naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07–1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87–1.92).

Conclusions

Histological inflammation in IBD predicted a small increase in short‐term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.

Subjects

MeSH terms (MEDLINE)

Inflammatory Bowel DiseasesFractures, BoneHumansFemaleMaleMiddle AgedAdultRisk FactorsCohort StudiesAgedYoung AdultBiopsyProportional Hazards ModelsAdrenal Cortex Hormones

Substances

Adrenal Cortex Hormones

Authors and institutions

  • Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden.
  • Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

ORCID profiles: Jordan Axelrad, Anders Forss, Jonas F Ludvigsson

Funding

  • NIDDK NIH HHS
  • Vetenskapsrådet
  • Svenska Sällskapet för Medicinsk Forskning

Cite

APA

Mårild, K., Söderling, J., Axelrad, J., Halfvarson, J., Forss, A., SWIBREG Study Group, Michaëlsson, K., Olén, O., & Ludvigsson, J. F. (2024). A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18275

Vancouver

Mårild K, Söderling J, Axelrad J, Halfvarson J, Forss A, SWIBREG Study Group, et al. A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18275

BibTeX
@article{Mrild2024,
  author = {Mårild, Karl and Söderling, Jonas and Axelrad, Jordan and Halfvarson, Jonas and Forss, Anders and SWIBREG Study Group, SWIBREG Study Group and Michaëlsson, Karl and Olén, Ola and Ludvigsson, Jonas F},
  title = {A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18275}
}
Start for free →